The University of Alabama at Birmingham School of Medicine

https://www.uab.edu/medicine/home/

 

Insights from 2023 EHA® Annual Meeting
Avatar

EHA® 2023 Insights: "Disease-Modifying Activity of Navtemadlin Correlated With Survival Outcomes in JAKi R/R Myelofibrosis Patients"

By Insights from 2023 EHA® Annual Meeting FEATURING Pankit Vachhani
By Insights from 2023 EHA® Annual Meeting FEATURING Pankit Vachhani
0 views
June 20, 2023
Comments 0
Login to view comments. Click here to Login
Videos
06:06
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "BMS-986393 (CC-95266), an Autologous GPRC5D…

Feat. S. Bal
17:47
The University of Alabama at Birmingham School of Medicine

Treating CML Patients With TKI Resistance vs. TKI Intolerance

Feat. O. Jamy
07:48
The University of Alabama at Birmingham School of Medicine

Intracranial Efficacy of RET Inhibitors in NSCLC

Feat. M. Khalil
23:11
International CML Foundation

ASH 2022 Highlights on CML: Biological Overview From iCMLf

Feat. R. Bhatia
14:56
International CML Foundation

ASH 2022 Highlights on CML: Q&A From iCMLf

Feat. R. Bhatia
12:44
Insights from 2023 EHA® Annual Meeting

EHA® 2023 Insights: "Disease-Modifying Activity of Navtemadlin …

Feat. P. Vachhani
23:03
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Neoadjuvant Therapy in TNBC - Where We Ar…

Feat. E. Stringer-Reasor
11:19
The University of Alabama at Birmingham School of Medicine

Mantle Cell Lymphoma: Unmet Needs & Latest Therapeutical Insights

Feat. A. Mehta
12:54
The University of Alabama at Birmingham School of Medicine

Tips and Tricks in Treatment of MCL: Choice of Regimens and Dosing C…

Feat. M. Narkhede
05:33
The University of Alabama at Birmingham School of Medicine

Addressing Challenges and Unmet Needs in Gastric Cancer

Feat. B. El-Rayes
14:01
The University of Alabama at Birmingham School of Medicine

Later-Line Treatment Options in CP-CML

Feat. O. Jamy